Go Pro

Immunovant (IMVT) Stock Forecast & Price Target

Immunovant logo
$41.20 -2.62 (-5.98%)
As of 08/28/2026 04:00 PM Eastern

Immunovant - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
1
Hold
3
Buy
7

Based on 11 Wall Street analysts who have issued ratings for Immunovant in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 1 has given a sell rating, 3 have given a hold rating, and 7 have given a buy rating for IMVT.

Consensus Price Target

$44.00
6.80% Upside
According to the 11 analysts' twelve-month price targets for Immunovant, the average price target is $44.00. The highest price target for IMVT is $62.00, while the lowest price target for IMVT is $28.00. The average price target represents a forecasted upside of 6.80% from the current price of $41.20.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for IMVT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Immunovant and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IMVT Analyst Ratings Over Time

TypeCurrent Forecast
8/30/25 to 8/30/26
1 Month Ago
7/31/25 to 7/31/26
3 Months Ago
6/1/25 to 6/1/26
1 Year Ago
8/30/24 to 8/30/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
7 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
8 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$44.00$42.11$37.33$35.20
Forecasted Upside6.80% Upside9.04% Upside13.61% Upside139.62% Upside
Consensus RatingModerate BuyModerate BuyHoldModerate Buy

IMVT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IMVT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Immunovant Stock vs. The Competition

TypeImmunovantHealthcare CompaniesBroader Market
Consensus Rating Score
2.55
2.30
2.53
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside6.80% Upside841.59% Upside13.05% Upside
News Sentiment Rating
Positive News

See Recent IMVT News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
8/25/2026
Cantor Fitzgerald logo
Cantor Fitzgerald
5 of 5 stars
 Reiterated RatingOverweight
8/4/2026
Brian Cheng
Brian Cheng
5 of 5 stars
Boost TargetOverweight$47.00 ➝ $50.00+25.98%
7/29/2026 UpgradeHold
7/6/2026 Reiterated RatingSell (D-)
6/30/2026Boost TargetBuy$57.00 ➝ $61.00+58.40%
5/26/2026Boost TargetBuy$44.00 ➝ $62.00+81.55%
5/22/2026Boost TargetHold$23.00 ➝ $30.00-13.57%
5/21/2026Boost TargetBuy$35.00 ➝ $40.00+12.49%
5/21/2026Boost TargetBuy$32.00 ➝ $43.00+20.92%
4/15/2026Boost TargetNeutral$29.00 ➝ $32.00+20.53%
1/6/2026UpgradePeer PerformOutperform$50.00+100.24%
7/28/2025Boost TargetNeutral$17.00 ➝ $18.00+7.40%
3/3/2025 Initiated CoverageHold$20.00-2.91%
12/19/2024 Lower TargetOverweight$47.00 ➝ $45.00+72.28%
10/10/2024Reiterated RatingOutperform$36.00+15.38%
10/9/2024 Boost TargetOutperform$47.00 ➝ $53.00+78.99%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 04:32 AM ET.


IMVT Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Immunovant is $44.00, with a high forecast of $62.00 and a low forecast of $28.00.

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last twelve months. There is currently 1 sell rating, 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IMVT shares.

According to analysts, Immunovant's stock has a predicted upside of 6.80% based on their 12-month stock forecasts.

Over the previous 90 days, Immunovant's stock had 1 upgrade by analysts.

Immunovant has been rated by research analysts at Cantor Fitzgerald, Citigroup, JPMorgan Chase & Co., Sanford C. Bernstein, and Weiss Ratings in the past 90 days.

Analysts like Immunovant more than other "healthcare" companies. The consensus rating for Immunovant is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how IMVT compares to other companies.


MarketBeat monitors more than a dozen sources for Immunovant analyst ratings, with the most recent rating issued on 8/25/2026.
From Our Partners